PT - JOURNAL ARTICLE AU - Yunfan Wen AU - Wen Wang AU - Yingna Ni AU - Yeqiao Gui AU - Zhihai Hu AU - Yi Wang AU - Mengke Han AU - Dongmin Zhang AU - Shi Shu AU - Shuang Zhou TI - Dose-effect relationship of ginger interposed moxibustion for allergic rhinitis: study protocol for a randomised, placebo-controlled and parallel clinical trial AID - 10.1101/2021.08.29.21262781 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.29.21262781 4099 - http://medrxiv.org/content/early/2021/08/31/2021.08.29.21262781.short 4100 - http://medrxiv.org/content/early/2021/08/31/2021.08.29.21262781.full AB - Introduction Allergic rhinitis has a severe impact on patients’ life quality, and the incidence rate keeps increasing. Moxibustion is widely used for treating allergic rhinitis, and quantity is the basis of moxibustion efficacy. The purpose of this study is to evaluate the relationship between the different quantities of moxibustion and the efficacy of moxibustion in the treatment of allergic rhinitis. This study may be conductive to the standardization of moxibustion and furnish the mechanism of dose-effect relationship of moxibustion with data and new ideas.Methods and analysis This randomized, placebo-controlled clinical trial will include 33 patients with allergic rhinitis who will be randomly assigned into three groups in a 1:1:1 ratio: high-dose moxibustion group, low-dose moxibustion group and sham moxibustion control group. All groups will be treated once every other day, 20 days for one treatment course. And the patients will receive treatment for 2 courses with an interval of 2 days between courses. We will conduct a follow-up 30 days later after completion of treatments. The primary outcome measure is Total Nasal Symptom Score, carried out at baseline, 3, 6 and 10 weeks. Secondary outcome measure is Rhino Conjunctivitis Quality of Life Questionnaire, carried out at baseline, 6 and 10 weeks.Ethics and dissemination This trail has been approved by the IRB of Shanghai TCM-Integrated Hospital, Shanghai University of TCM. The results of the trial will be disseminated in peer-reviewed journals.Trial registration number ChiCTR2100050373; Pre-results.Strengths and limitations of this studyA randomised, placebo-controlled and parallel clinical trial will be conducted to test if ginger interposed moxibustion would have curative effect on allergic rhinitis and reveal the preliminary dose-effect relationship of moxibustion.This study will set high-dose moxibustion group and low-dose moxibustion group to test if more quantities of ginger interposed moxibustion would achieve better therapeutic effects on allergic rhinitis.Further study should be carried out to test if the curative effect of ginger interposed moxibustion would be positively correlated with the quantities.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2100050373Funding StatementThis study was financially supported by the Three-Year Action Plan of Shanghai for the Development of Traditional Chinese Medicine (ZY(2018-2020)CCCX-2001-05), The 14th Batch of College Students' Innovation and Entrepreneurship Project of Shanghai University of TCM (no.202110268093).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Shanghai TCM-Integrated Hospital, Shanghai University of TCMAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be open to the public one year after finishing the trial.